C
Angiotensin II
Novel & Emerging BiomarkersLab test / biomarkerriskpartially modifiable
11
evidence score
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 4.8meta-analyses: 0trials: 6genetic: 0MR bonus:
References (2)
0 meta-analyses / systematic reviews- Angiotensin II and cell cycle regulation. — Hypertension (Dallas, Tex. : 1979) 2004 · PMID 14967829
- Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. — Cardiovascular research 2004 · PMID 15820196
Clinical trials (3)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT04493359 | Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial | TERMINATED | INTERVENTIONAL | Renin-angiotensin system inhibitors |
| NCT00459771 | Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab | COMPLETED | INTERVENTIONAL | AT1 blocker candesartan, Placebo |
| NCT00696384 | An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension | COMPLETED | INTERVENTIONAL | Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo |
Genetic associations (0)
None linked.